Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease (BIO-AGE)
Theme Group:
Clinical Trials and Therapeutics
Funding:
TopMD Precision Medicine Limited, as part of a UKRI/Innovate UK award
About the project:
The gastrointestinal tract in humans is one of the largest interfaces between the host and the environment. Different bacteria in the gut have been linked with longevity and healthy ageing. However, some of these bacteria can cause activation of the body’s immune system, which has the potential to cause harm. Research has shown that activation of the immune system is linked with developing Alzheimer’s disease (AD) and Parkinson’s disease (PD) later in life. This project will apply cutting edge measurement of gut bacteria genes from older people with Alzheimer’s disease, Parkinson’s disease, and Dementia with Lewy bodies. Alongside our commercial partner, TopMD, we will combine the predictive power of gut bacteria genes and blood gene expression signatures with the aim to develop the first ever combined test of gut bacteria and genes that will be used to help diagnose brain diseases.
Key iDeAC expertise:
Dr Jessica Teeling
Neuroinflammation and infection
Dr Jay Amin
Clinical Trials
Dr Christopher Kipps
Clinical Research lead
Related projects:
Use of antisense oligonucleotide in Progressive supranuclear palsy
Treating impulsivity in people with progressive supranuclear palsy
Using electronic patient records to examine patient outcomes in Dementia with Lewy bodies
Combining Memantine and Cholinesterase inhibitors in Lewy body dementia treatment trial (COBALT)
Phase 1 trial of bepranemab in progressive supranuclear palsy
Permeability of the blood-brain barrier in Alzheimer’s disease (PEBBAL) measured using dynamic contrast-enhanced MRI: a pilot study
Diagnostic biomarkers of gut microbiome-associated phenotypes predictive of healthy aging and neurodegenerative disease (BIO-AGE)